WO2023111322 - GLYCO-ENGINEERED CAR-T CELLS
National phase entry:
Publication Number
WO/2023/111322
Publication Date
22.06.2023
International Application No.
PCT/EP2022/086474
International Filing Date
16.12.2022
Title **
[English]
GLYCO-ENGINEERED CAR-T CELLS
[French]
CELLULES CAR-T GLYCO-MODIFIÉES
Applicants **
VIB VZW
Suzanne Tassierstraat 1
9052 Gent, BE
UNIVERSITEIT GENT
Sint-Pietersnieuwstraat 25
9000 Gent, BE
Inventors
CALLEWAERT, Nico
Begijnhoflaan 15
9850 Nevele, BE
FESTJENS, Nele
Bruggestraat 35
9690 Kluisbergen, BE
DE BOUSSER, Elien
Guldenmeers 13
9050 Gent, BE
Priority Data
21215482.7
17.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1519 | |
| EPO | Filing, Examination | 5896 | |
| Japan | Filing | 529 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5635 |
Total: 14154 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
gene, as to provide for surface glycan structures devoid of tetra-antennary N-glycans, which results in a sustained memory when applied in immunotherapy, to cure cancer, reduce (recurrent) tumor growth and tumor burden, as well as to prevent relapse. The invention further relates to methods for manufacturing of those CAR-T cells, wherein addition of low amounts of DMSO during activation and expansion ex vivo skews T cell populations to a more predominant memory phenotype, thereby providing for improved glycol- engineered CAR-T cell compositions for adoptive T cell transfer.[French]
muté, de manière à fournir des structures de glycane de surface dépourvues de N-glycanes tétra-antennaires, ce qui permet d'obtenir une mémoire soutenue lors d'une application en immunothérapie, de guérir le cancer, de réduire la croissance tumorale (récurrente) et la charge tumorale, ainsi que d'empêcher une rechute. L'invention concerne en outre des procédés de fabrication de ces cellules CAR-T, l'ajout de faibles quantités de DMSO pendant l'activation et l'expansion ex vivo orientant les populations de lymphocytes T vers un phénotype de mémoire plus prédominant, ce qui permet d'obtenir des compositions de cellules CAR-T modifiées par glycol améliorées pour un transfert adoptif de lymphocytes T.